The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor*

Received for publication, May 19, 2005, and in revised form, June 20, 2005
Published, JBC Papers in Press, June 23, 2005, DOI 10.1074/jbc.M505513200

Jihui Ai‡, Paula Smith‡, Shuwei Wang‡, Ping Zhang‡, and X. Long Zheng¶††

From the ‡Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia and ¶The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

ADAMTS13 limits platelet-rich thrombosis by cleaving von Willebrand factor at the Tyr1605–Met1606 bond. Previous studies showed that ADAMTS13 truncated after spacer domain remains proteolytically active or hyperactive. However, the relative contribution of each domain within the proximal carboxyl terminus of ADAMTS13 in substrate recognition and specificity is not known. We showed that a metalloprotease domain alone was unable to cleave the Tyr–Met bond of glutathione S-transferase (GST)-VWF73-H substrate in 3 h, but it did cleave the substrate at a site other than the Tyr–Met bond after 16–24 h of incubation. Remarkably, the addition of even one or several proximal carboxyl-terminal domains of ADAMTS13 restored substrate specificity. Full proteolytic activity, however, was not achieved until all of the proximal carboxyl-terminal domains were added. The addition of TSP1 2–8 repeats and two CUB domains did not further increase proteolytic activity. Furthermore, ADAMTS13 truncated after the spacer domain with or without metalloprotease domain bound GST-VWF73-H with a $K_d$ of ~7.0 or 13 nM, comparable with full-length ADAMTS13 ($K_d$ = 4.6 nM). Metalloprotease domain did not bind GST-VWF73-H detectably, but the disintegrin domain, first TSP1 repeat, Cys-rich domain, and spacer domain bound GST-VWF73-H with $K_d$ values of 489, 136, 121, and 108 nM, respectively. These proximal carboxyl-terminal domains dose-dependently inhibited cleavage of fluorescent resonance energy transfer (FRET)-VWF73 by full-length ADAMTS13 and ADAMTS13 truncated after the spacer domain. These data demonstrated that the proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for recognition and cleavage of von Willebrand factor between amino acid residues Asp1595 and Arg1606.

ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat) (1–6) cleaves von Willebrand factor (VWF) at the Tyr1605–Met1606 bond of the central A2 subunit (7, 8). Inability to cleave newly synthesized and released “unusually large” VWF multimers from endothelial cells or platelets due to deficiency of ADAMTS13 proteolytic activity may result in an accumulation of the unusually large VWF multimers (9), leading to formation of disseminated platelet-rich microthrombi in small arteries, a characteristic pathologic feature of thrombotic thrombocytopenic purpura.

For purposes of discussion, ADAMTS13 may be divided arbitrarily into four functionally distinct regions: the metalloprotease, the proximal, the middle, and the distal carboxyl-terminal regions. The metalloprotease domain is the catalytic center, containing a characteristic HExXXHXXGXXHID sequence that coordinates Zn$^{2+}$ or Ca$^{2+}$ binding (1–6, 10). The proximal carboxyl-terminal region consists of a disintegrin domain, a first thrombospondin type 1 (TSP1) repeat, a Cys-rich domain, and a spacer domain. The middle and distal carboxyl-terminal domains of ADAMTS13 have seven additional TSP1 repeats and two CUB (C1r/C1s, urinary epidermal growth factor, bone morphogenetic protein) domains (3, 6, 10, 11).

Studies have shown that ADAMTS13 truncated after the spacer domain remains proteolytically active toward plasma VWF in the presence of 1.5 M urea and low ionic strength (12, 13) and appears to be hyperactive toward unusually large VWF that are newly released from cultured endothelial cells under flow conditions (14). In addition, the autoantibodies identified in patients with idiopathic thrombotic thrombocytopenic purpura all react with the Cys-rich domain and spacer domain (15, 16). These data suggest a critical role of the proximal C terminus of ADAMTS13 in substrate recognition in vivo. However, the relative contribution of each domain within the proximal carboxyl-terminal region of ADAMTS13 to substrate recognition and enzymatic activity remains unclear, as the assays using plasma VWF in the presence of urea are extremely slow and lacking in sensitivity. For example, ADAMTS13 mutants truncated after the Cys-rich domain are essentially inactive toward plasma VWF (12, 13), making it impossible to assess the contribution of the shorter truncated ADAMTS13 mutants. In addition, denaturing reagents added into the assay system may partially inactivate ADAMTS13 protease while unfolding multimeric VWF substrate to expose the cleavage site.

To further determine the relative contribution of each domain within the proximal carboxyl-terminal domains of ADAMTS13 in substrate recognition and specificity, we employed more sensitive peptide substrates, GST-VWF73-H and FRETs-VWF73. In each case, a 73-amino acid peptide (Asp1595–Arg1606) derived from the central A2 domain of VWF was either phosphate-buffered saline; MES, 4-morpholineethanesulfonic acid; bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; FRETs, fluorescent resonance energy transfer.
The disintegrin domain, the first TSP1 repeat, the Cys-rich domain, and the spacer domain. The products were gel-purified and ligated into Champion™ pET151/D directional TOPO vector according to manufacturer’s protocol (Invitrogen). Each construct starts with the sequence MHHHHHHHGKPPIPNNLPLGLDSTENLTQF (the His6 tag and the AcTEV protease cleavage region are underlined, and the V5 epitope is bolded). A linker amino acid sequence (−IDPFTM−) immediately precedes the specific domain of ADAMTS13.

Preparation of Recombinant VWF73 Substrate—Bacterial strain BL21 Star™ (DE3) (Stratagene) was transformed with 5 ng of pD-ET-VWF73 incubated with SOC medium (Invitrogen), 20 mM glucose, 2.5% yeast extract, 10 mM sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 mM magnesium sulfate, 20 mM glucose) at 37 °C for 1 h. After being selected overnight at 37 °C on an agar plate containing 50 µg/ml ampicillin, a single colony was selected and expanded to a 50-ml and then a 1-liter culture. After being induced by the addition of 1% D-thiogalactoside (Sigma) at 37 °C for 4 h, the cells were harvested and lysed with 50 µg/ml lysozyme. The recombinant GST-VWF73-H was purified by affinity chromatography with 5 ml of Hitrap nickel-chelating column (Amersham Biosciences), followed by a 1-ml glutathione-Sepharose 4B column (Amersham Biosciences). The purified GST-VWF73-H was diluted (1:20) with phosphate-buffered saline (PBS), pH 7.4, and dialyzed against PBS overnight. The purity of GST-VWF73-H was determined by electrophoresis on a 15% Tris-HCl SDS-gel and Coomassie blue staining. The protein concentration was determined using a BCA kit (Pierce) according to the manufacturer’s protocol.

Expression and Preparation of Recombinant ADAMTS13 and Mutants—Full-length ADAMTS13 and its mutants were prepared from COS7 cells (13) or human embryonic kidney (HEK) 293 cells. Briefly, cells were seeded at 50–80% confluency 1 day prior to transfection in 10 cm-dishes in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. The conditioned medium were collected and concentrated 10–20-fold with a Centricon-10 or Centriprep-30 (Millipore). The cells were dissociated from the dish by trypsinization and transferred onto a 48-well plate after 1:20 dilution. The stable clones were selected with G418 (0.5 µg/ml) for 14 days. The clones expressing recombinant proteins were determined by Western blotting with anti-V5 (Invitrogen). The concentration of ADAMTS13 and the mutants in the conditioned medium were quantified by Western blotting with anti-V5 as described previously, using a purified protein (Positope™, IgG fraction) as a standard (13, 20, 21).

Recombinant ADAMTS13 and the mutants were also purified from the serum-free conditioned media of HEK293, which stably expressed ADAMTS13 and various mutants by affinity chromatography with DEAE (Amersham Biosciences), amonnia sulfate precipitation, nickel-nitrioltriacetic acid-agarose (Invitrogen), and Superose-6 (Amersham Biosciences) gel filtration on an AKTA™ FPLC liquid chromatography system (Amersham Biosciences). The concentration of purified ADAMTS13 was determined by using a BCA kit (Pierce) with bovine serum albumin as reference.

Preparation of the Proximal Carboxy-terminal Domains of ADAMTS13 from Escherichia coli—The bacterial strain BL21Ai was transformed by 1 ng of plasmid encoding the disintegrin domain (His-V5-Ds), the first TSP1 repeat (His-V5-TSP1), the Cys-rich domain (His-V2-CysR), and the spacer domain (His-V5-Spa). A single colony was selected and expanded to 1 liter of culture. After being induced by 0.5 mM isopropyl-β-D-thiogalactoside (Fisher Scientific) for 4 h at 37 °C, the cells were harvested by centrifugation at 3,500 rpm for 15 min. The inclusion bodies of the E. coli cells were isolated with B-Per reagents according to the manufacturer’s recommendation (Pierce) and lysed with 8 µl urea in 100 µl NaH2PO4, 10 µl Triton X-100, pH 8.0. Then 10 ml of the cell lystate was added dropwise to 200 ml of refolding buffer (50 mM MES, pH 6.0, 240 mM NaCl, 10 mM KCl, 1 mM EDTA, 0.5 mM arginine, 0.4 mM sucrose, 0.5% Triton X-100, 0.05% polyethylene glycol 16,000 the in presence of 1 mM fresh GSH and 0.1 mM fresh GSSG) (Sigma) according to the protocol from the Athena enzyme system (Athena Environmental Sciences, Inc., Baltimore, MD). The protein was added to the refolding buffer with gentle stirring at 37 °C at 37 °C for 12 h. After being dialyzed against 20 mM Tris-HCl, 150 mM NaCl, pH 8.0, the recombinant domains of ADAMTS13 were purified by affinity chromatography with nickel-nitrioltriacetic acid-agarose (Invitrogen). The imidazole in the eluate was removed by PD-10 gel filtration column per the manufacturer’s instruction (Amersham Biosciences). SDS-gel electrophoresis and Coomassie Blue staining determined the purity of the protein. The BCA reagents determined the protein concentration.

**FIG. 1.** The domain structure of ADAMTS13 and various carboxy-terminal truncated mutants. Full-length ADAMTS13 (FL) consists of a metallocarboxypeptidase domain (M), a disintegrin domain (D), the first TSP1 repeat (T1), a Cys-rich domain (C), and a spacer domain (S) followed by seven more TSP1 repeats (T2–8) and two CUB domains. The DTCS domains are located in the proximal C terminus of ADAMTS13. The TSP1 2–8 and two CUB domains are located in the middle and the distal C termini of ADAMTS13, respectively. Each construct is tagged at its C terminus by a V5-His epitope derived from pcDNA3.1 V5-His TOPO.
Cleavage of GST-VWF73-H by ADAMTS13 Its Mutants—Purified GST-VWF73-H (200 ng) was incubated with 16 nM ADAMTS13 and the mutants in 50 mM Tris•HCl, 50 mM NaCl, pH 8.0, at 37 °C for 3 h and 24 h. Boiling for 5 min with sample buffer containing 20 mM Tris•HCl, pH 7.5, 0.5% SDS, and 5% β-mercaptoethanol stopped the reaction. One-fifth of the digested material was separated by 12% Tris•HCl, SDS-gel and transferred onto a polyvinylidene difluoride membrane (pore size 0.22 μm). After being blocked by 2.5% nonfat milk (Pathmark, Philadelphia, PA) in 20 mM Tris•HCl, pH 7.5, 150 mM NaCl, and 0.5% Tween 20 (TBST) for 30 min, the membrane was incubated overnight at room temperature with rabbit anti-GST IgG (1:1,000) (Molecular Probes) (17) followed by anti-rabbit IgG, peroxidase-conjugated (1:25,000) (Amersham Biosciences) at room temperature for 2 h. After being washed three times with TBST, the bound secondary antibodies were detected by the SuperSignalTM chemiluminescent ECL detection system (Pierce) (13). The lumignoroms were scanned, and the relative amount of proteins was determined by densitometry using NIH Image (developed at the National Institutes of Health and available on the Internet at rsb.info.nih.gov/nih-image/).

Cleavage of Plasma VWF by ADAMTS13 and Its Mutants—The proteolytic cleavage of plasma VWF at the Tyr–Met bond by ADAMTS13 and various mutants was determined by electrophoresis on a 5% Tris•HCl SDS-gel under denatured and reduced conditions followed by Western blotting with a peroxidase-conjugated anti-VWF IgG (DAKO) as described (13).

ADAMTS13-VWF73 Binding—A 96-well microtiter plate (Nunc) was coated with or without 50 mM GST-VWF73-H diluted in PBS overnight. After being blocked by 2.5% bovine serum albumin in PBS, ADAMTS13 and various mutants or domains were added and incubated at 37 °C for 2–3 h in 50 mM Tris•HCl, 50 mM NaCl, pH 7. After being washed three times with PBS, the bound ADAMTS13 and mutants were quantified by peroxidase-conjugated anti-V5 IgG (Invitrogen) followed by a chromogenic substrate, O-phenylenediamine dihydrochloride-hydrogen peroxide (OPD•H2O2, Sigma). After subtracting the nonspecific binding, the reagents detected the domains of ADAMTS13 bound to GST-VWF73-H.

Competition Inhibition Assay—The affinity-purified proximal carboxy-terminal domains as a whole (construct DTCs) (0, 0.5, 1, 2, and 4 nM) or individually (constructs Dis, TSP1, CyR, and Spa) (0, 200, 500, and 1000 nM) were incubated with FRETs-VWF73 (1 μM) (Peptides International, Lexington, KY) for 15 min at 30 °C. ADAMTS13 (0.5 nM) or ADAMTS13 mutant (MDTCS) (1 nM) was added into the reaction containing 5 mM bis-Tris, 25 mM CaCl2, and 0.05% Tween 20, pH 6.0. The generation of fluorescence was determined by a fluorescence spectrophotometer (λex = 340 nm and λem = 450 nm) every 5 min for 2 h (Molecular Devices, Sunnyvale, CA). The residual proteolytic activity was calculated from the slope using normal human plasma as a standard. In the absence of competitive inhibitors, the proteolytic activity was defined as 100% of that of normal human plasma (18).

RESULTS

Metalloprotease Domain of ADAMTS13 Alone Did Not Cleave VWF Specifically—Consistent with previous studies using plasma VWF as a substrate (12, 13), a recombinant metalloprotease domain of ADAMTS13 alone at a concentration of 16 nM, 2–5 times that of plasma concentration (∼2–5 nM) (1, 13), did not cleave GST-VWF73-H (Fig. 2A) or FRETs-VWF73 (data not shown) specifically at 37 °C in 3 h, during which time the substrate was completely cleaved by full-length recombinant ADAMTS13 at the same concentration (Fig. 2A, lanes 3 and 4; Figs. 3 and 4). However, upon a prolonged incubation (∼16–24 h), the metalloprotease domain did cleave GST-VWF73-H, but at a site other than the predicted Tyr–Met bond, generating an amino-terminal product approximately 3 kDa smaller than expected (Fig. 2B, lanes 3 and 4, and Fig. 3B). Such cleavage of GST-VWF73-H was not observed using the same amount of concentrated (10-fold) serum-free conditioned medium that was collected from COS7 cells transfected with vector alone (Fig. 2, A and B, lanes 1 and 2). The cleavage of GST-VWF73-H by the metalloprotease domain could be abrogated by the addition of 10 mM EDTA (Fig. 2B, lane 3), suggesting a metal ion-dependent proteolysis. These data demonstrated unexpectedly that recombinant metalloprotease domain of ADAMTS13 produced from transfected cells is an active enzyme but alone is not sufficient for recognition and specific cleavage of the Tyr–Met bond of VWF.

Addition of Proximal Carboxy-terminal Domains of ADAMTS13 Restores Specificity—To assess the role of the proximal carboxy-terminal domains of ADAMTS13 in substrate recognition, we determined the proteolytic cleavage of GST-VWF73-H by recombinant full-length ADAMTS13 and various truncation or deletion mutants. We showed that the addition of even one of the proximal carboxy-terminal domains, such as the disintegrin domain (construct MD), the first TSP1 repeat (construct MT), or the spacer domain (construct MS), immediately restores specific cleavage of GST-VWF73-H at the Tyr–Met bond (Fig. 3). The addition of two or more proximal carboxy-terminal domains to the metalloprotease domain (constructs MCS and MTCs) was still not sufficient to restore full proteolytic activity (Fig. 3). The proteolytic activity of all of these mutants lacking one or several domains between the catalytic domain and the spacer domain was quite low. Only a minimal amount of GST-VWF73-H was cleaved in 3 h of incubation, but the cleavage occurred specifically at the Tyr–Met bond as judged by the molecular weight of cleaved products, even after a prolonged incubation for up to 24 h (Fig. 3). None of these constructs (MD, MT, MS, MCS, and MTCs) cleaved plasma VWF in the presence of 1.5 M urea and low ionic strength (Table I). These data suggested that each one of the proximal carboxy-terminal domains of ADAMTS13 participates in substrate recognition or is required for conformation.

When the disintegrin domain, the first TSP1 repeat, the Cys-rich, domain, and the spacer domain were sequentially added to the metalloprotease domain, proteolytic activity toward GST-VWF73-H (Fig. 4) or FRETs-VWF73 (data not
ADAMTS13 Substrate Specificity

29431

Fig. 3. Cleavage of GST-VWF73-H by ADAMTS13 mutants lacking one or several proximal carboxyl-terminal domains. GST-
VWF73-H (200 ng) was incubated with 14 nM ADAMTS13 (FL) and the various carboxyl-terminal deleted mutants for 2 h. Lanes 1-7 correspond to the constructs negative control (Con), M, MD, MDT, MDTCS, and delCUB, respectively, as illustrated in Fig. 1. The arrow indicates the intact substrate, and the arrowhead indicates the cleaved product. B, the signal on the luminogram was quantified by densitometry with ImageJ and is shown as the means ± S.D. from three independent experiments. Sequential addition of the proximal carboxyl-terminal domains gradually increases the proteolytic activity.

Fig. 4. Relative proteolytic activity of ADAMTS13 and the carboxyl-terminal truncated mutants. A, Western blot with anti-GST detects cleavage of GST-VWF73-H (200 ng) by 14 nM full-length ADAMTS13 (FL) and the various carboxyl-terminal deleted mutants for 2 h. Lanes 1-7 correspond to the constructs negative control (Con), M, MD, MDT, MDTCS, and delCUB, respectively, as illustrated in Fig. 1. The arrow indicates the intact substrate, and the arrowhead indicates the cleaved product. B, the signal on the luminogram was quantified by densitometry with ImageJ and is shown as the means ± S.D. from three independent experiments. Sequential addition of the proximal carboxyl-terminal domains gradually increases the proteolytic activity.

Cleavage of GST-VWF73-H and plasma VWF by ADAMTS13 and various mutants

The signs +++, ++, +, and +/- indicate >50%, 10–50%, and <10% activity, respectively, compared with normal human plasma. S, indicates the predicted Tyr–Met bond was cleaved; NS, indicates the bond other than the Tyr–Met bond was cleaved. The domain structures of full-length ADAMTS13 (FL) and the mutants (from M to delCUB) are illustrated in detail in Fig. 1. The cleavage of GST-VWF73-H or plasma VWF was determined by 12% or 5% Tris-HCl SDS-gel and Western blotting with anti-GST IgG and chemiluminescent reagents determined the cleavage of GST-VWF73-H. The closed arrow indicates intact substrate (38.4 kDa), and the open arrowheads indicate the cleaved product specifically at the Tyr–Met bond (B–D).

Table I

| Constructs | Cleavage of VWF73 | Cleavage of VWF, 16 h |
|------------|-------------------|----------------------|
| M          | –                 | +                    |
| MD         | +/−               | +                    |
| MT         | +                 | +                    |
| MS         | –                 | −                    |
| MDT        | +                 | +                    |
| MDTCS      | +/−               | +                    |
| MTCS       | +/−               | +                    |
| MDTCS      | +                 | +                    |
| delCUB     | +                 | +                    |
| FL         | +                 | +                    |

shown) gradually increased while the specificity was maintained. ADAMTS13 truncated after the first TSP1 repeat (construct MDT), however, cleaved GST-VWF73-H, specifically at the Tyr–Met bond initially (3 h) (Fig. 2A, lane 8), but cleaved additional two peptidyl bonds (Phe–Asn and Lys–Lys) upon a prolonged incubation (24 h) (Fig. 2B, lane 8). The peptidyl bonds cleaved by construct MDT were confirmed by amino-terminal protein sequencing of the carboxyl-terminal portion of the cleaved product. Full proteolytic activity toward GST-VWF73-H (Fig. 4) or FRETS-VWF73 (data not shown) and plasma VWF (Table I) was not achieved until all of the proximal carboxyl-terminal domains were added to the metalloprotease domain. Notably, the proteolytic activity of ADAMTS13 truncated after the spacer domain (construct MDTCS) toward GST-VWF73-H (Fig. 4), FRETS-VWF73 (data not shown), or plasma VWF (Table I) is nearly equal to that of full-length ADAMTS13. The further addition of the 2–8 TSP1 repeats and the CUB domains did not alter the proteolytic activity and specificity (Fig. 4 and Table I). These data support a hypothesis that the proximal carboxyl-terminal domains of ADAMTS13 determine the substrate recognition and specificity, whereas the middle and distal carboxyl-terminal domains are dispensable, at least in vitro.

Binding of ADAMTS13 and Mutants to GST-VWF73-H—To determine the relative contribution of the proximal carboxy-terminal domains of ADAMTS13 in direct substrate binding and recognition, we have determined the interaction between ADAMTS13 (or various domains) and GST-VWF73-H with an enzyme-linked immunosorbent assay. We showed that full-length ADAMTS13, MDTCS, and DTCS all bind GST-VWF73-H, but not GST alone, in a dose-dependent and saturable manner, with $K_d$ values of 4.6 ± 1.3, 7.0 ± 1.9, and 13 ± 2.1 nM, respectively (Fig. 5A and Table II). However, the metalloprotease did not bind GST-VWF73-H detectably at a concentration of 100 nM, suggesting that the proximal carboxy-terminal domains contain the major binding sites for the 73-amino acid peptide (Asp$^{595}$–Arg$^{668}$) of VWF.

Furthermore, an individual recombinant disintegrin domain, first TSP1 repeat, Cys-rich domain, and spacer domain, all
Binding of ADAMTS13 and mutants or of the individual domains of ADAMTS13 to immobilized GST-VWF73-H. A, affinity-purified ADAMTS13 mutant deleted after the spacer domain (MDTCS) at concentrations of 0 to 50 nM was added to immobilized GST-VWF73-H (closed circle) or bovine serum albumin (open circle). B, full-length ADAMTS13 and ADAMTS13 truncated after the spacer domain with (MDTCS) or without the metalloprotease domain (DTCS) bound GST-VWF73 to saturation. The metalloprotease domain did not bind GST-VWF73-H detectably. Purified individual proximal carboxyl-terminal domains of ADAMTS13 including the disintegrin domain (Dis), the first TSP1 repeat (TSP1), the Cys-rich domain (CysR), and the spacer domain (Spa) also bound immobilized GST-VWF73-H to saturation.

### Table II

| Constructs | $K_d$ (nM) |
|------------|------------|
| FL         | 4.3 ± 1.3  |
| MDTCS      | 7.0 ± 1.9  |
| DTCS       | 13 ± 2.1   |
| M          | ND         |
| Dis        | 489 ± 42   |
| TSP1       | 136 ± 4.0  |
| CysR       | 121 ± 5.0  |
| Spa        | 108 ± 14   |

$K_d$ values were calculated as described under “Experimental Procedures.” ND, $K_d$ for this construct was not determined. Entries represent the average ± S.E. ($n = 3$).

Tagged by His-V5 epitope at the N amino terminus, bound GST-VWF73-H dose-dependently to saturation with $K_d$ values of 489 ± 42, 136 ± 4, 121 ± 5, and 108 ± 14 nM, respectively (Fig. 5B and Table II).

The binding interaction between the individual domains of the proximal carboxyl terminus of ADAMTS13 and GST-VWF73-H was further verified in solution by a GST pull-down assay. When GST-VWF73-H (0 or 250 nM) was incubated without or with 50 nM affinity-purified disintegrin domain, first TSP1 repeat, Cys-rich domain, and spacer domain for 2 h, each one of the proximal carboxyl-terminal domains of ADAMTS13 could be pulled down by glutathione-Sepharose 4B and detected by Western blotting with anti-V5 IgG (Fig. 6). As a negative control, GST protein alone at a concentration of 250 nM did not bind either one of the ADAMTS13 domains (data not shown). These data suggested that a specific binding interaction does occur between the proximal carboxyl-terminal domains of ADAMTS13 and the 73-amino acid peptide between Asp$^{1595}$ and Arg$^{1605}$ of VWF.

**Competition of Cleavage of FRETS-VWF73 by the Proximal Carboxyl-terminal Domain or Domains**—To demonstrate that the binding interaction described above is functionally relevant, a competition assay between MDTCS and the proximal carboxyl-terminal domains for cleavage of FRETS-VWF73 was performed. The FRETS-VWF73 has been shown to be by far the most sensitive and highly specific assay to detect ADAMTS13 activity and inhibition. When affinity-purified recombinant disintegrin, first TSP1 repeat, Cys-rich, and spacer domains at concentrations of 0 to 1000 nM were preincubated with FRETS-VWF73 (1 μM) for 15 min, the proteolytic cleavage of FRETS-VWF73 by MDTCS was inhibited dose-dependently (Fig. 7A) with concentrations to inhibit 50% of MDTCS activity ($IC_{50}$) of 900, 800, 800, and 500 nM, respectively. However, when the proximal carboxyl terminus of ADAMTS13 expressed as a single fragment (DTCS) was added into the reaction, the cleavage of FRETS-VWF73 by ADAMTS13 and MDTCS was almost completely inhibited with $IC_{50}$ values of 1.2 and 0.75 nM, respectively (Fig. 7B), suggesting a collaborative effort of all of these proximal carboxyl-terminal domains of ADAMTS13 in substrate binding.

**Discussion**

In this study, we have demonstrated that a metalloprotease domain of ADAMTS13 alone does not cleave GST-VWF73-H or FRETS-VWF73 in 3 h, but it does cleave a peptide bond ~3 kDa upstream of the expected Tyr–Met bond (Fig. 2B). Remarkably, the addition of even one of the proximal carboxyl-terminal domains, such as the disintegrin domain (construct MD), the first TSP1 repeat (construct MT), or the spacer domain (construct MS), immediately restores specificity (Figs. 2–4). The addition of one or more proximal carboxyl-terminal domains to

---

2 X. L. Zheng, P. Smith, J. Ai, and S. Shelat, unpublished data.
disintegrin domain (in ADAMTS13 including the VWF73 by ADAMTS13 truncated after the spacer domain (Spa) dose-dependently block cleavage of FRETS-VWF73 by full-length ADAMTS13 (FL) and MDTCS. The percentage of residual ADAMTS13 activity was plotted on the y axis, whereas the concentrations of the disintegrin, TSP1, Cys-rich, and spacer or DTCs domains were plotted on the x axis. The values entered represent the average of three independent experiments.

the growing constructs did not much improve the proteolytic activity (constructs MCS and MTCs) (Fig. 3). The proteolytic activity of all of these mutants, including MD, MT, MS, MCS, and MTCs lacking one or several proximal carboxyl-terminal domains, remained quite low compared with that of full-length ADAMTS13 and MDTCS (Figs. 3 and 4). However, the proteolytic activity of MDTCS was nearly equal to that of full-length ADAMTS13 as determined by GST-VWF73-H (Fig. 4), FRETS-VWF73 (data not shown), and plasma VWF (Table I), suggesting that each one of the proximal carboxyl-terminal domains participates in substrate recognition and is required for cleavage of VWF between amino acid residues Asp1595 and Arg1668.

We conclude that the proximal carboxyl-terminal domains including the disintegrin domain, the first TSP1 repeat, the Cys-rich domain, and the spacer domain determine the substrate specificity and are all required for recognition and cleavage of VWF between amino acid residues Asp1595 and Arg1668.

Acknowledgments—We thank Dr. Han-Mou Tsai for providing the pDES15-VWF73 construct for generating GST-VWF73-H substrate. We also thank Dr. Sriram Krishnaswamy for helpful discussions.

REFERENCES

1. Gerritsen, H. E., Robles, B., Lammle, B., and Furlan, M. (2001) Blood 98, 1654–1661
2. Fujikawa, K., Suzuki, H., McMullen, B., and Chung, D. (2001) Blood 98, 1662–1666
3. Zheng, X., Chung, D., Takayama, T. K., Majerus, E. M., Sadler, J. E., and Fujikawa, K. (2001) J. Biol. Chem. 276, 41059–41063
4. Cal, S., Obaya, A. J., Llamazares, M., Garabaya, C., Quesada, V., and Lopez-Otin, C. (2002) Gene 293, 49–62
5. Plaimauer, B., Zimmermann, K., Volkel, D., Antoine, G., Kerschbaumer, R., Jenab, P., Furlan, M., Gerritsen, H., Lammle, B., Schwarz, H. P., and Schefflinger, F. (2002) Blood 100, 3626–3632
6. Levy, G. G., Nichols, W. C., Lian, E. C., Foroud, T., McLintick, J. N., McGee, B. M., Yang, A. Y., Siemieniak, D. R., Stark, K. R., Gruppo, R., Sarode, R., Shurin, S. B., Chandrasekaran, V., Stahlber, S. P., Sahio, H., Bouhassira, E. E., Upshaw, J. D., Jr., Ginsburg, D., and Tsai, H. M. (2001) Science 213, 413–416.

FIG. 7. Inhibition of ADAMTS13 activity by recombinant proximal carboxyl-terminal domains of ADAMTS13. A, affinity-purified proximal carboxyl-terminal domains of ADAMTS13 including the disintegrin domain (Dis), first TSP1, Cys-rich domain (CysR), and spacer domain (Spa) dose-dependently block cleavage of FRETS-VWF73 by ADAMTS13 truncated after the spacer domain (MDTCS). B, the proximal carboxyl-terminal domain as a single fragment (DTCS) dose-dependently blocks the cleavage of FRETS-VWF73 by full-length ADAMTS13 (FL) and MDTCS. The percentage of residual ADAMTS13 activity was plotted on the y axis, whereas the concentrations of the disintegrin, TSP1, Cys-rich, and spacer or DTCs domains were plotted on the x axis. The values entered represent the average of three independent experiments.

ADAMTS13 Substrate Specificity

The proteolytic activity of MDTCS and full-length ADAMTS13 was nearly equal (Fig. 4), and so is the binding affinity toward GST-VWF73-H (Fig. 5 and Table II) and plasma VWF (21). These data further confirmed the notion that the middle and distal carboxyl-terminal domains of ADAMTS13 are not required for recognition and cleavage of VWF in vitro (12, 13). It, however, does not rule out the potential role of the middle and the distal carboxyl-terminal domains of ADAMTS13 in the modulation of ADAMTS13-VWF binding and proteolytic activity in vivo. Tao et al. (14) have recently shown that the cleavage of unusually large VWF multimers secreted from cultured endothelial cells by a ADAMTS13 mutant lacking the distal CUB domains is in fact increased under flow. In addition, truncation after the seventh TSP1 repeat increases the affinity for VWF by about 2-fold (21). Mutations in the TSP1 1–8 repeats and/or CUB domains resulting in thrombotic microangiopathy (6, 29–32) suggest the biological importance of these domains in vivo. This finding is not contradictory to our results with carboxyl-terminal truncated mutants, as several point mutations in the TSP1 repeats 2–8 and the CUB domains resulted in intracellular retention of the mutant ADAMTS13, and therefore no ADAMTS13 activity in plasma could be detected (6, 29, 33, 34).

Although the exact amino acid residues on the VWF73 peptide responsible for ADAMTS13 binding are not clear, it is reasonable to believe that ADAMTS13 may bind the very last nine amino acid residues of the VWF73 peptide, because deletion of the nine amino acid residues at the carboxyl terminus of VWF73 (i.e., VWF64) renders the peptide uncleavable (17). More interestingly, the $K_d$ for ADAMTS13 and MDTCS to bind GST-VWF73-H (Table II) is $\sim$ 3–4-fold smaller than for ADAMTS13 and MDTCS to bind plasma VWF ($K_d \sim 16$ and 24 nM, respectively), as determined by a similar approach (21); this suggests that the domains surrounding the VWF73 peptide, particularly around the cleavage site, such as domain A1 (22), part of domain A2, domain A3 (23), and the carboxyl terminus of VWF, may negatively regulate ADAMTS13-VWF binding. Even in the presence of denaturing reagents such as urea and guanidine, the cleavage site on VWF may not be fully exposed to or become freely accessible by ADAMTS13. The domain A1 appears in the way of ADAMTS13 to cleave the Tyr–Met bond, as the addition of soluble platelet glycoprotein 1b to denatured VWF (22) increases cleavage of VWF by ADAMTS13. The binding peptide or cleavage site may be better exposed by shear stress under flow or domain deletion than by denaturing reagents or immobilization of VWF to the plastic surface, as the cleavage of unusually large VWF multimers by ADAMTS13 under flow conditions occurs within minutes (14, 23, 24), rather than hours or days, in the presence of 1.5 M urea (13, 25–28).
7. Furlan, M., Robles, R., and Lammle, B. (1996) Blood 87, 4223–4234
8. Tsai, H. M. (1996) Blood 87, 4235–4244
9. Moake, J. L., Rudy, C. K., Troll, J. H., Weinstein, M. J., Colannino, N. M., Azzar, J., Seder, R. H., Hong, S. L., and Deykin, D. (1982) N. Engl. J. Med. 307, 1432–1435
10. Soejima, K., Mimura, N., Hirashima, M., Maeda, H., Hamamoto, T., Nakagaki, T., and Nozaki, C. (2001) J. Biochem. (Tokyo) 130, 475–480
11. Bork, P., and Beckmann, G. (1993) J. Mol. Biol. 231, 539–545
12. Soejima, K., Matsumoto, M., Kokame, K., Yagi, H., Ishizashi, H., Maeda, H., Nozaki, C., Miyata, T., Fujimura, Y., and Nakagaki, T. (2003) Blood 102, 3232–3237
13. Zheng, X., Nishio, K., Majorus, E. M., and Sadler, J. E. (2003) J. Biol. Chem. 278, 30136–30141
14. Tao, Z., Wang, Y., Choi, H., Bernardo, A., Nishio, K., Sadler, J. E., Lopez, J. A., and Deng, J. F. (2005) Blood, 106, 141–143
15. Klaus, C., Platimauer, B., Studt, J. D., Dornier, F., Lammle, B., Mannucci, P. M., and Scheffinger, F. (2004) Blood 103, 4514–4519
16. Luken, B. M., Turenhout, E. A., Hulstein, J. J., Van Mourik, J. A., Fijnheer, R., and Voorberg, J. (2005) Thromb. Haemostasis 93, 267–274
17. Kokame, K., Matsumoto, M., Fujimura, Y., and Miyata, T. (2003) Blood 103, 607–612
18. Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A., and Miyata, T. (2005) Br J Haematol 129, 93–100
19. Zhou, W., and Tsai, H. M. (2004) Thromb. Haemostasis 91, 806–811
20. Majerus, E. M., Zheng, X., Tuley, E. A., and Sadler, J. E. (2003) J. Biol. Chem. 278, 46643–46648
21. Majerus, E. M., Anderson, P. J., and Sadler, J. E. (2005) J. Biol. Chem. 280, 71773–71778
22. Nishio, K., Anderson, P. J., Zheng, X. L., and Sadler, J. E. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 10578–10583
23. Deng, J. F., Moake, J. L., Bernardos, A., Fujikawa, K., Ball, C., Nolasco, L., Lopez, J. A., and Cruz, M. A. (2003) J. Biol. Chem. 278, 29633–29639
24. Deng, J. F., Moake, J. L., Nolasco, L., Bernardos, A., Arceneaux, W., Shrimpton, C. N., Schade, A. J., McIntire, L. V., Fujikawa, K., and Lopez, J. A. (2002) Blood 100, 4033–4039
25. Furlan, M., and Lammle, B. (1998) Basiliiers Clin. Haematol. 11, 509–514
26. Furlan, M., Robles, R., Solenthaler, M., and Lammle, B. (1998) Blood 91, 2839–2846
27. Veyradier, A., Obert, B., Houllier, A., Meyer, D., and Girma, J. P. (2001) Blood 98, 1765–1772
28. Zheng, X. L., Richard, K. M., Goodnough, L. T., and Sadler, J. E. (2004) Blood 103, 4043–4049
29. Kokame, K., Matsumoto, M., Soejima, K., Yagi, H., Ishizashi, H., Funato, M., Tamai, H., Konno, M., Kamide, K., Kawano, Y., Miyata, T., and Fujimura, Y. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 11902–11907
30. Assink, K., Schiphorst, R., Allford, S., Karpman, D., Etzioni, A., Brichard, B., van de Kar, N., Mennens, L., and van den Heuvel, L (2003) Kidney Int. 63, 1995–1999
31. Schneppenheim, R., Budde, U., Oyen, F., Angerhaus, D., Aumann, V., Drewke, E., Hassenplug, W., Haberle, J., Kentouche, K., Kohne, E., Kurnik K., Mueller-Wiefel, D., Ohser, T., Santer, R., and Sykora, K. W. (2003) Blood 101, 1845–1850
32. Matsumoto, M., Kokame, K., Soejima, K., Miura, M., Hayashi, S., Fujii, Y., Iwai, A., Ito, E., Tseu, Y., Takeda-Shitaka, M., Iwadate, M., Umeyama, H., Yagi, H., Ishizashi, H., Banno, F., Nakagaki, T., Miyata, T., and Fujimura, Y. (2003) Blood 103, 1305–1310
33. Pimanda, J. E., Maekawa, A., Wind, T., Paxton, J., Chesterman, C. N., and Hogg, P. J. (2004) Blood 103, 627–629
34. Kokame, K., and Miyata, T. (2004) Semin. Hematol. 41, 34–40